XM, Amerika Birleşik Devletleri'nde ikamet edenlere hizmet sunmamaktadır.
R
R

Roche


Haberler

Biotech firm Recursion to buy smaller peer Exscientia for $688 million

Biotech firm Recursion to buy smaller peer Exscientia for $688 million By Anirban Sen NEW YORK, Aug 8 (Reuters) - Recursion Pharmaceuticals RXRX.O , a biotech firm which uses artificial intelligence to discover new drug candidates, has agreed to buy smaller rival Exscientia EXAI.O for $688 million in an all-stock deal, according to a statement seen by Reuters.
B
N
R
S

Europe's STOXX 600 jumps 1% on banks-led recovery; Novo Nordisk slumps

UPDATE 2-Europe's STOXX 600 jumps 1% on banks-led recovery; Novo Nordisk slumps For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window Novo Nordisk logs steepest decline since Aug 2022 Puma slumps after narrowing FY profit outlook Continental up after Q2 results beat Just Eat Takeaway top STOXX 600 gainer after rating upgrade Roche considering divesting $1.9 bln cancer data startup- FT STOXX 600 up 1.5% Updated at 1550 GMT By Ankika Biswas and
B
C
J
P
R
A
E
F
S
U
G

Green shoots for stocks

LIVE MARKETS-Green shoots for stocks Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com . GREEN SHOOTS FOR STOCKS European stocks are set for a positive start to Wednesday after jittery investors were reassured after The Bank of Japan's deputy governor played down the chance of a near-term interest rate hike.
H
L
R
E
F
G

Swiss stocks - Factors to watch on August 7

Swiss stocks - Factors to watch on August 7 ZURICH/GDANSK, Aug 7(Reuters) - Here are some of the main factors that may affect Swiss stocks on Wednesday: COMPANY STATEMENTS ROCHE HOLDING ROG.S Roche considering divesting $1.9 bln cancer data startup, FT reports. LOGITECH INTERNATIONAL LOGN.S Matteo Anversa to join Logitech as CFO. ECONOMY Swiss July Forex Reserves due at 0700 GMT.
L
R

Roche considering divesting $1.9 bln cancer data startup, FT reports

UPDATE 3-Roche considering divesting $1.9 bln cancer data startup, FT reports Adds details from FT report in paragraphs 4-5 and Citi response in paragraph 7 Aug 7 (Reuters) - Swiss pharmaceutical company Roche ROG.S is considering divesting cancer data specialist Flatiron Health, the Financial Times reported on Wednesday, citing people familiar with the matter.
C
G
R

Roche considering divesting $1.9 bln cancer data startup, FT reports

Roche considering divesting $1.9 bln cancer data startup, FT reports Aug 7 (Reuters) - Swiss pharmaceutical company Roche ROG.S is considering divesting cancer data specialist Flatiron Health, the Financial Times reported on Wednesday, citing people familiar with the matter. Roche had paid $1.9 billion for New-York based Flatiron Health in 2018. Re
R

Sangamo Therapeutics rises on licensing agreement with Genentech

BUZZ-Sangamo Therapeutics rises on licensing agreement with Genentech ** Shares of gene therapy developer Sangamo Therapeutics SGMO.O surge 60.83% to $1.23 ** Co says it has entered into a license agreement with Roche's ROG.S Genentech to develop therapies for neurodegenerative diseases ** Sangamo has granted Genentech an exclusive license to Sanga
R

Arkema, Man Group, Shell

EUROPE RESEARCH ROUNDUP- Arkema, Man Group, Shell Aug 2 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Arkema, Man Group and Shell, on Friday. HIGHLIGHTS * Arkema SA AKE.PA : HSBC raises target price to EUR 105 from EUR 103 * Berkeley Group BKGH.L : Jefferies raises target price to 4,936p from 4,834p * Diageo Plc DGE.L : Morgan Stanley cuts target price to 2200p from 2380p * Man Group Plc EMG.L : Peel Hunt cuts to add from buy * Sh
A
A
A
A
A
B
B
B
B
B
C
C
C
D
E
E
M
R
S
S
U
A
B
T

Regeneron beats quarterly results on strong demand for eczema, eye treatments

Regeneron beats quarterly results on strong demand for eczema, eye treatments Aug 1 (Reuters) - Drugmaker Regeneron Pharmaceuticals REGN.O exceeded estimates for second-quarter revenue and profit on Thursday, driven by strong demand for its top-selling eczema and eye drugs. The company has been upgrading patients who use its eye treatment, Eylea, to a higher-dose version to beat the impact from cheaper biosimilars available in the market and rival drugs.
B
R
R
S

BofA sees buying opportunity in Novo amid recent pullback

BUZZ-BofA sees buying opportunity in Novo amid recent pullback ** BofA Global Research sees "macroeconomic pullback" as a buying opportunity for investors in Novo Nordisk NOVOb.CO , confirming its "buy" rating on the obesity drugs maker ** It notes the Danish pharma giant's shares have fallen about 15% since highs in July , while it sees growth cat
R

European Commission Approves Roche’S Vabysmo For Treatment Of RVO

BRIEF-European Commission Approves Roche’S Vabysmo For Treatment Of RVO July 30 (Reuters) - ROCHE HOLDING AG ROG.S : EUROPEAN COMMISSION APPROVES ROCHE’S VABYSMO FOR TREATMENT OF RETINAL VEIN OCCLUSION (RVO) VABYSMO IS ALREADY APPROVED IN SEVERAL COUNTRIES, INCLUDING US AND JAPAN ADDITIONAL SUBMITTED DATA SHOWS THAT UP TO 60% OF PEOPLE RECEIVIN
R

Roche Holding AG Says Fast-Tracking Clinical Development Of Obesity Portfolio - Spokesperson

BRIEF-Roche Holding AG Says Fast-Tracking Clinical Development Of Obesity Portfolio - Spokesperson July 29 (Reuters) - Roche Holding AG ROG.S : ROCHE HOLDING AG - FAST-TRACKING CLINICAL DEVELOPMENT OF OBESITY PORTFOLIO - SPOKESPERSON ROCHE HOLDING AG - CT-996 WILL BE MOVING TOWARDS PHASE 2 TRIALS NEXT YEAR - SPOKESPERSON ROCHE HOLDING AG - AIM TO B
R

Roche Closes Acquisition Of Lumiradx’S Point Of Care Technology

BRIEF-Roche Closes Acquisition Of Lumiradx’S Point Of Care Technology July 29 (Reuters) - ROCHE HOLDING AG ROG.S : ROCHE CLOSES ACQUISITION OF LUMIRADX’S POINT OF CARE TECHNOLOGY TO EXPAND ACCESS TO DIAGNOSTIC TESTING IN PRIMARY CARE Source text for Eikon: ID:nGNEb5BzHp Further company coverage: ROG.S (Gdansk Newsroom)
R

Roche to fast-track weight loss drugs to compete with rivals, FT reports

UPDATE 1-Roche to fast-track weight loss drugs to compete with rivals, FT reports Adds details from FT report throughout; background in paragraphs 2 and 4 July 29 (Reuters) - Swiss drugmaker Roche ROG.S plans to accelerate the development of its anti-obesity drugs to challenge rivals like Eli Lilly LLY.N and Novo Nordisk NOVOb.CO in the booming market, the Financial Times reported on Monday.
R

Swiss stocks - Factors to watch on July 29

Swiss stocks - Factors to watch on July 29 ZURICH/GDANSK, July 29 (Reuters) - Here are some of the main factors that may affect Swiss stocks on Monday: COMPANY STATEMENTS ROCHE HOLDING ROG.S Roche plans to fast-track weight loss pill to compete with rivals, FT reports. ANALYSTS' VIEWS HOLCIM AG HOLN.S - Jefferies raises target price to CHF 85.5 from CHF 84 ECONOMY SNB data on Swiss sight deposits due at 0800 GMT.
R

Roche To Fast-Track Weight Loss Pill To Compete With Rivals - FT

BRIEF-Roche To Fast-Track Weight Loss Pill To Compete With Rivals - FT July 29 (Reuters) - ROCHE TO FAST-TRACK WEIGHT LOSS PILL TO COMPETE WITH RIVALS - FT Source text: tinyurl.com/28xkkxtn Further company coverage: ROG.S
R

Roche to fast-track weight loss pill to compete with rivals, FT reports

Roche to fast-track weight loss pill to compete with rivals, FT reports July 29 (Reuters) - Swiss pharmaceutical company Roche ROG.S plans to fast-track its anti-obesity drugs to challenge Eli Lilly LLY.N and Novo Nordisk NOVOb.CO after unveiling promising data for a weight-loss pill, the Financial Times reported on Monday. Thomas Schinecker, CEO o
R

European shares fall as earnings deluge disappoints

UPDATE 2-European shares fall as earnings deluge disappoints STOXX 600 down 0.7% Universal Music Group slumps as streaming growth disappoints Kering down after weak H2 forecast Besi tumbles as Q3 outlook disappoints Unilever gains after H1 profit beat Updated at 1600 GMT By Pranav Kashyap and Shashwat Chauhan July 25 (Reuters) - European shares closed lower on Thursday as a slate of downbeat earnings reports in several sectors including tech and luxury weighed, while a global run for safe haven
K
L
N
R
R
S
A
E
F
U
G

STOXX 600 drops to 12-week low as earnings fail to impress

LIVE MARKETS-STOXX 600 drops to 12-week low as earnings fail to impress STOXX 600 down 1.2% CAC 40 hits lowest since Jan UMG tumbles after results European semis weak Healthcare shines Wall St futures steady Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com STOXX 600 DROPS TO 12-WEEK LOW AS EARNINGS FAIL TO IMPRESS European equities are in the red on Thursday as the decline in glob
A
R
S
V
E
F
U
G

Roche seen up after guidance hike, H1 profit beat

BUZZ-Roche seen up after guidance hike, H1 profit beat ** Shares of Roche Holding ROG.S are seen up 2.2% in pre-market trade after the Swiss company lifted its 2024 profit guidance and posted H1 profit beat ** "A positive surprise", which suggests a 2% to 5% potential consensus profit upgrades, Jefferies says on the EPS guidance hike ** H1 Group co
R



Şartlar

Popüler varlıklar

Bildirim: XM Group şirketlerinin her biri yalnızca gerçekleştirme hizmeti ve online yatırım platformumuza erişim sağlar. Herhangi bir kişinin web sitesinde bulunan veya web sitesi üzerinden sağlanan içeriği görüntülemesine ve/veya kullanmasına izin vermek, bu hizmeti değiştirmek veya genişletmek amaçlı değildir ve bu hizmeti ne değiştirir ne de genişletir. Bu tür erişim ve kullanım her zaman şunlara tabidir: (i) Şartlar ve Koşullar; (ii) Risk Uyarıları ve (iii) Tam Bildirim. Bu nedenle bu tür içerikler yalnızca genel bilgi amacıyla sağlanır. Özellikle, online yatırım platformumuzun içeriklerinin finans piyasalarında herhangi bir işleme girmek için bir teşvik veya bir teklif olmadığını lütfen dikkate alın. Herhangi bir finans piyasasında yatırım yapmak sermayeniz için önemli düzeyde risk taşır.

Online yatırım platformumuzda yayınlanan tüm materyaller yalnızca eğitim/bilgilendirme amaçlıdır ve finansal tavsiye, yatırım vergisi veya yatırım tavsiyesi ve önerileri ya da yatırım fiyatlarımızın kaydı veya herhangi bir finansal enstrümanda işlem yapılması için bir teklif veya teşvik ya da talep edilmemiş finansal promosyonları içermez ve içerdiği şeklinde bir değerlendirme yapılmamalıdır.

Görüşler, haberler, araştırma, analizler, fiyatlar, diğer bilgiler veya bu web sitesinde bulunan üçüncü taraf sitelere verilen bağlantılar gibi her türlü üçüncü taraf içeriğin yanı sıra XM tarafından hazırlanan içerik de “olduğu gibi” esasına göre, genel piyasa yorumu olarak sağlanır ve bir yatırım tavsiyesi oluşturmaz. Herhangi bir içeriğin yatırım araştırması olarak yorumlanmasıyla ilgili olarak, içeriğin bağımsız yatırım araştırmasını desteklemek üzere tasarlanmış yasal gerekliliklere uygun hazırlanmadığını ve bu amacın güdülmediğini, aynı şekilde ilgili yasalar ve mevzuatlar kapsamında pazarlama iletişimi olarak değerlendirileceğini dikkate almalı ve kabul etmelisiniz. Buradan erişebileceğiniz Bağımsız Olmayan Yatırım Araştırması Bildirimimizi ve yukarıdaki bilgilerle ilgili Risk Uyarımızı okuduğunuzdan ve anladığınızdan emin olun.

Risk uyarısı: Sermayeniz risk altında. Kaldıraçlı ürünler herkese uygun olmayabilir. Lütfen Risk Bildirimi'mizi dikkate alın.